Trinity Biotech plc Sponsored ADR (TRIB)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Trinity Biotech's Redesigned CGM Sensor Favored by New Clinical Data
TRIB's needle-free CGM+ sensor shows accurate 15-day results with no calibration, slashing costs and boosting access.
Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript
Trinity Biotech Plc (NASDAQ:TRIB ) Q3 2024 Earnings Conference Call November 15, 2024 10:00 AM ET Company Participants Eric Ribner - Investor Relations John Gillard – President, Chief Executive Officer Louise Tallon - Chief Financial Officer Conference Call Participants James Sidoti - Sidoti & Company Paul Nouri – Noble Equity Funds Operator Greetings. Welcome to the Trinity Biotech Third Quarter 2024 Earnings Conference Call.
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.
Trinity Biotech plc Sponsored ADR (TRIB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Trinity Biotech plc Sponsored ADR ever had a stock split?
Trinity Biotech plc Sponsored ADR Profile
| Professional Services Industry | Industrials Sector | John Gillard CEO | NASDAQ (NGS) Exchange | 896438306 CUSIP |
| IE Country | 380 Employees | 1 Jul 2015 Last Dividend | 27 Aug 2025 Last Split | 18 Aug 1995 IPO Date |
Overview
Trinity Biotech plc focuses on the acquisition, development, manufacture, and marketing of medical diagnostic products aimed at the clinical laboratory and point-of-care (POC) segments within the diagnostic market across the Americas, Africa, Asia, and Europe. Specializing in the detection of infectious diseases, diabetes monitoring, and the diagnosis of autoimmune conditions, the company has established a prominent position since its inception in 1992. Headquartered in Bray, Ireland, Trinity Biotech is committed to serving public health authorities, non-governmental organizations, clinical and reference laboratories by leveraging its direct sales force and a comprehensive network of independent distributors and strategic partners.
Products and Services
- Clinical Laboratory Products:
These include diagnostic tests and instruments for detecting infectious diseases, such as Lyme disease, sexually transmitted diseases like syphilis and herpes, SARS-CoV-2, Epstein-Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella, and various other viral pathogens. Additionally, Trinity Biotech offers in-vitro diagnostic testing products for hemoglobin A1c, crucial for monitoring and diagnosing diabetes, and identifying individuals at risk of developing this condition.
- Immunodiagnostics:
Trinity Biotech develops, manufactures, and markets a broad range of products across several formats, including immunofluorescence assays (IFA), enzyme-linked immunosorbent assays (ELISA), western blot, and line immunoassays. These products are essential tools for the diagnosis of autoimmune and infectious diseases.
- Reagent Products:
The company also provides a variety of reagent products for diagnosing liver and kidney diseases, as well as hemolytic anemia. These include tests for ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase.
- Sales of Raw Materials:
Beyond finished diagnostic products, Trinity Biotech sells raw materials to the life sciences industry and research institutes, supporting a wide range of scientific and medical research efforts.
Contact Information
